DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

Diabetes Care- United States

doi 10.2337/dc09-1914

Full Text

Abstract

Available in

Date

Authors

Publisher

American Diabetes Association

Related search

Safety, Tolerability and Sustained Weight Loss Over 2 Years With the Once-Daily Human GLP-1 Analog, Liraglutide

International Journal of Obesity
NutritionEndocrinologyDieteticsMedicineMetabolismDiabetes
2013English

RYGB Produces More Sustained Body Weight Loss and Improvement of Glycemic Control Compared With VSG in the Diet-Induced Obese Mouse Model

Obesity Surgery
NutritionEndocrinologyDieteticsSurgeryMetabolismDiabetes
2017English

Improved Treatment Satisfaction and Weight-Related Quality of Life With Exenatide Once Weekly or Twice Daily

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2009English

Exenatide Extended-Release: A Once Weekly Treatment for Patients With Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2014English

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

Advances in Therapy
MedicinePharmacology
2020English

Once-Weekly Exenatide as Adjunct Treatment of Type 1 Diabetes Mellitus in Patients Receiving Continuous Subcutaneous Insulin Infusion Therapy

Canadian Journal of Diabetes
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2014English

Adherence to Liraglutide Once Daily or Exenatide Once Weekly Over a 12-Month Period Among Commercially Insured Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Family Support and Weight-Loss Strategies Among Adolescents Reporting Sustained Weight Loss

Public Health Nutrition
NutritionDieteticsPublic HealthEnvironmentalMedicineOccupational Health
2012English

Exenatide Once-Weekly Injection for the Treatment of Type 2 Diabetes in Chinese Patients: Current Perspectives

Therapeutics and Clinical Risk Management
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy